Boston Trust Walden Corp Has $18.51 Million Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH

Boston Trust Walden Corp reduced its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 13.1% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 944,789 shares of the company’s stock after selling 142,477 shares during the period. Boston Trust Walden Corp owned 2.12% of Amphastar Pharmaceuticals worth $18,508,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. Clark Capital Management Group Inc. bought a new position in Amphastar Pharmaceuticals during the third quarter worth about $7,560,000. SG Americas Securities LLC bought a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter valued at about $2,504,000. Denali Advisors LLC raised its position in shares of Amphastar Pharmaceuticals by 56.9% in the 4th quarter. Denali Advisors LLC now owns 211,765 shares of the company’s stock valued at $5,671,000 after acquiring an additional 76,765 shares during the period. Algert Global LLC raised its position in shares of Amphastar Pharmaceuticals by 216.1% in the 3rd quarter. Algert Global LLC now owns 392,902 shares of the company’s stock valued at $10,471,000 after acquiring an additional 268,612 shares during the period. Finally, Bridge City Capital LLC boosted its stake in Amphastar Pharmaceuticals by 72.8% during the 4th quarter. Bridge City Capital LLC now owns 235,485 shares of the company’s stock worth $6,306,000 after acquiring an additional 99,227 shares during the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AMPH has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, May 8th. Bank of America reissued an “underperform” rating and set a $20.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, June 29th. Zacks Research lowered shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, June 22nd. Barclays lowered their price objective on shares of Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating for the company in a research report on Wednesday, June 3rd. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $22.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, April 21st. Five analysts have rated the stock with a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $22.00.

Amphastar Pharmaceuticals Price Performance

AMPH stock opened at $19.64 on Friday. The stock has a 50-day moving average price of $19.70 and a two-hundred day moving average price of $22.67. Amphastar Pharmaceuticals, Inc. has a 1 year low of $16.65 and a 1 year high of $31.26. The stock has a market cap of $865.93 million, a PE ratio of 11.83, a price-to-earnings-growth ratio of 3.86 and a beta of 0.89. The company has a current ratio of 3.85, a quick ratio of 2.82 and a debt-to-equity ratio of 0.79.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.28). The firm had revenue of $171.17 million for the quarter, compared to analyst estimates of $173.46 million. Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%. Equities analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.41 EPS for the current fiscal year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.